Anti‐tumor immunity induced by tumor cells express a membrane‐bound form of IL‐2 and SDF‐1

References

• Allione, A, Consalvo, M, Nanni, P, Lollini, PL, Cavallo, F., Giovarelli, M, Forni, M, Gulino, A, Colombo, MP, Dellabona, P, et al., 1994. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)‐2, IL‐4, IL‐6, IL‐7, IL‐10, tumor necrosis factor alpha, granulocyte‐macrophage colony‐stimulating factor, and gamma‐interferon gene or admixed with conventional adjuvants, Cancer Res 54 (1994), pp. 6022–6026.
   PubMed Web of Science ®Google Scholar
• Armstrong, CA, Botella, R, Galloway, TH, Murray, N, Kramp, JM, Song, IS, and Ansel, JC, 1996. Antitumor effects of granulocyte‐macrophage colony‐stimulating factor production by melanoma cells, Cancer Res 56 (1996), pp. 2191–2198.
   PubMed Web of Science ®Google Scholar
• Assenmacher, M, Scheffold, A, Schmitz, J, Segura Checa, JA, Miltenyi, S, and Radbruch, A, 1996. Specific expression of surface interferon‐gamma on interferon‐gamma producing T cells from mouse and man, Eur J Immunol 26 (1996), pp. 263–267.
   PubMed Web of Science ®Google Scholar
• Atkins, MB, Lotze, MT, Dutcher, JP, Fisher, RI, Weiss, G, Margolin, K, Abrams, J, Sznol, M, Parkinson, D, Hawkins, M, et al., 1999. High‐dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993, J Clin Oncol 17 (1999), pp. 2105–2116.
   PubMed Web of Science ®Google Scholar
• Baskar, S, Nabavi, N, Glimcher, LH, and Ostrand‐Rosenberg, S, 1993. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor‐specific immunity, J Immunother 14 (1993), pp. 209–215.
   PubMed Web of Science ®Google Scholar
• Blankenstein, T, Rowley, DA, and Schreiber, H, 1991. Cytokines and cancer: experimental systems, Curr Opin Immunol 3 (1991), pp. 694–698.
   PubMedGoogle Scholar
• Browning, JL, Ngam‐ek, A, Lawton, P, DeMarinis, J, Tizard, R, Chow, EP, Hession, C, O'Brine‐Greco, B, Foley, SF, and Ware, CF, 1993. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface, Cell 72 (1993), pp. 847–856.
   PubMed Web of Science ®Google Scholar
• Campbell, JJ, and Butcher, EC, 2000. Chemokines in tissue‐specific and microenvironment‐specific lymphocyte homing, Curr Opin Immunol 12 (2000), pp. 336–341.
   PubMed Web of Science ®Google Scholar
• Chang, MR, Lee, WH, Choi, JW, Park, SO, Paik, SG, and Kim, YS, 2005. Antitumor immunity induced by tumor cells engineered to express a membrane‐bound form of IL‐2, Exp Mol Med 37 (2005), pp. 240–249.
   PubMedGoogle Scholar
• Chen, K, Braun, S, Lyman, S, Fan, Y, Traycoff, CM, Wiebke, EA, Gaddy, J, Sledge, G, Broxmeyer, HE, and Cornetta, K, 1997. Antitumor activity and immunotherapeutic properties of Flt3‐ligand in a murine breast cancer model, Cancer Res 57 (1997), pp. 3511–3516.
   PubMed Web of Science ®Google Scholar
• Cimino, AM, Palaniswami, P, Kim, AC, and Selvaraj, P, 2004. Cancer vaccine development: protein transfer of membrane‐anchored cytokines and immunostimulatory molecules, Immunol Res 29 (2004), pp. 231–240.
   PubMed Web of Science ®Google Scholar
• Colombo, MP, Modesti, A, Parmiani, G, and Forni, G, 1992. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte‐T‐lymphocyte cross‐talk, Cancer Res 52 (1992), pp. 4853–4857.
   PubMed Web of Science ®Google Scholar
• Dilloo, D, Bacon, K, Holden, W, Zhong, W, Burdach, S, Zlotnik, A, and Brenner, M, 1996. Combined chemokine and cytokine gene transfer enhances antitumor immunity, Nat Med 2 (1996), pp. 1090–1095.
   PubMed Web of Science ®Google Scholar
• Dranoff, G, Jaffee, E, Lazenby, A, Golumbek, P, Levitsky, H, Brose, K, Jackson, V, Hamada, H, Pardoll, D, and Mulligan, RC, 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte‐macrophage colony‐stimulating factor stimulates potent, specific, and long‐lasting anti‐tumor immunity, Proc Natl Acad Sci USA 90 (1993), pp. 3539–3543.
   PubMed Web of Science ®Google Scholar
• Dunussi‐Joannopoulos, K, Zuberek, K, Runyon, K, Hawley, RG, Wong, A, Erickson, J, Herrmann, S, and Leonard, JP, 2002. Efficacious immunomodulatory activity of the chemokine stromal cell‐derived factor 1 (SDF‐1): local secretion of SDF‐1 at the tumor site serves as T‐cell chemoattractant and mediates T‐cell‐dependent antitumor responses, Blood 100 (2002), pp. 1551–1558.
   PubMed Web of Science ®Google Scholar
• el‐Shami, KM, Tzehoval, E, Vadai, E, Feldman, M, and Eisenbach, L, 1999. Induction of antitumor immunity with modified autologous cells expressing membrane‐bound murine cytokines, J Interferon Cytokine Res 19 (1999), pp. 1391–1401.
   PubMedGoogle Scholar
• Emoto, M, Mittrucker, HW, Schmits, R, Mak, TW, and Kaufmann, SH, 1999. Critical role of leukocyte function‐associated antigen‐1 in liver accumulation of CD4+NKT cells, J Immunol 162 (1999), pp. 5094–5098.
   PubMed Web of Science ®Google Scholar
• Fearon, ER, Pardoll, DM, Itaya, T, Golumbek, P, Levitsky, HI, Simons, JW, Karasuyama, H, Vogelstein, B, and Frost, P, 1990. Interleukin‐2 production by tumor cells bypasses T helper function in the generation of an antitumor response, Cell 60 (1990), pp. 397–403.
   PubMed Web of Science ®Google Scholar
• Gabrilovich, DI, Ciernik, IF, and Carbone, DP, 1996. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor‐bearing hosts, Cell Immunol 170 (1996), pp. 101–110.
   PubMed Web of Science ®Google Scholar
• Gansbacher, B, Zier, K, Daniels, B, Cronin, K, Bannerji, R, and Gilboa, E, 1990. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity, J Exp Med 172 (1990), pp. 1217–1224.
   PubMed Web of Science ®Google Scholar
• Hillman, GG, Slos, P, Wang, Y, Wright, JL, Layer, A, De Meyer, M, Yudelev, M, Che, M, and Forman, JD, 2004. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma, Cancer Gene Ther 11 (2004), pp. 61–72.
   PubMedGoogle Scholar
• Huang, AY, Golumbek, P, Ahmadzadeh, M, Jaffee, E, Pardoll, D, and Levitsky, H, 1994. Role of bone marrow‐derived cells in presenting MHC class I‐restricted tumor antigens, Science 264 (1994), pp. 961–965.
   PubMed Web of Science ®Google Scholar
• Jackaman, C, Bundell, CS, Kinnear, BF, Smith, AM, Filion, P, van Hagen, D, Robinson, BW, and Nelson, DJ, 2003. IL‐2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor‐associated vasculature: a novel mechanism for IL‐2, J Immunol 171 (2003), pp. 5051–5063.
   PubMed Web of Science ®Google Scholar
• Kim, YS, Sonn, CH, Paik, SG, and Bothwell, AL, 2000. Tumor cells expressing membrane‐bound form of IL‐4 induce antitumor immunity, Gene Ther 7 (2000), pp. 837–843.
   PubMedGoogle Scholar
• Kimura, K, Nishimura, H, Hirose, K, Matsuguchi, T, Nimura, Y, and Yoshikai, Y, 1999. Immunogene therapy of murine fibrosarcoma using IL‐15 gene with high translation efficiency, Eur J Immunol 29 (1999), pp. 1532–1542.
   PubMedGoogle Scholar
• Kriegler, M, Perez, C, DeFay, K, Albert, I, and Lu, SD, 1988. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF, Cell 53 (1988), pp. 45–53.
   PubMed Web of Science ®Google Scholar
• Kumar, A, Humphreys, TD, Kremer, KN, Bramati, PS, Bradfield, L, Edgar, CE, and Hedin, KE, 2006. CXCR4 physically associates with the T cell receptor to signal in T cells, Immunity 25 (2006), pp. 213–224.
   PubMed Web of Science ®Google Scholar
• Kundig, TM, Bachmann, MF, DiPaolo, C, Simard, JJ, Battegay, M, Lother, H, Gessner, A, Kuhlcke, K, Ohashi, PS, Hengartner, H, et al., 1995. Fibroblasts as efficient antigen‐presenting cells in lymphoid organs, Science 268 (1995), pp. 1343–1347.
   PubMed Web of Science ®Google Scholar
• Kurt‐Jones, EA, Fiers, W, and Pober, JS, 1987. Membrane interleukin 1 induction on human endothelial cells and dermal fibroblasts, J Immunol 139 (1987), pp. 2317–2324.
   PubMed Web of Science ®Google Scholar
• Leonard, JP, Sherman, ML, Fisher, GL, Buchanan, LJ, Larsen, G, Atkins, MB, Sosman, JA, Dutcher, JP, Vogelzang, NJ, and Ryan, JL, 1997. Effects of single‐dose interleukin‐12 exposure on interleukin‐ 12‐associated toxicity and interferon‐gamma production, Blood 90 (1997), pp. 2541–2548.
   PubMed Web of Science ®Google Scholar
• Lollini, PL, and Forni, G, 2003. Cancer immunoprevention: tracking down persistent tumor antigens, Trends Immunol 24 (2003), pp. 62–66.
   PubMedGoogle Scholar
• Lu, X, Kallinteris, NL, Li, J, Wu, S, Li, Y, Jiang, Z, Hillman, GG, Gulfo, JV, Humphreys, RE, and Xu, M, 2003. Tumor immunotherapy by converting tumor cells to MHC class II‐positive, Ii protein‐negative phenotype, Cancer Immunol Immunother 52 (2003), pp. 592–598.
   PubMed Web of Science ®Google Scholar
• Luo, L, Chapoval, AI, Flies, DB, Zhu, G, Hirano, F, Wang, S, Lau, JS, Dong, H, Tamada, K, Flies, AS, et al., 2004. B7‐H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen‐specific CD8+ cytolytic T cells, J Immunol 173 (2004), pp. 5445–5450.
   PubMed Web of Science ®Google Scholar
• Marr, RA, Addison, CL, Snider, D, Muller, WJ, Gauldie, J, and Graham, FL, 1997. Tumour immunotherapy using an adenoviral vector expressing a membrane‐bound mutant of murine TNF alpha, Gene Ther 4 (1997), pp. 1181–1188.
   PubMedGoogle Scholar
• Mizoguchi, H, O'Shea, JJ, Longo, DL, Loeffler, CM, Mc Vicar, DW, and Ochoa, AC, 1992. Alterations in signal transduction molecules in T lymphocytes from tumor‐bearing mice, Science 258 (1992), pp. 1795–1798.
   PubMed Web of Science ®Google Scholar
• Mohle, R, Bautz, F, Denzlinger, C, and Kanz, L, 2001. Transendothelial migration of hematopoietic progenitor cells. Role of chemotactic factors, Ann N YAcad Sci 938 (2001), pp. 26–34, discussion.
   PubMedGoogle Scholar
• Nanki, T, Hayashida, K, El‐Gabalawy, HS, Suson, S, Shi, K, Girschick, HJ, Yavuz, S, and Lipsky, PE, 2000. Stromal cell‐derived factor‐ 1‐CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium, J Immunol 165 (2000), pp. 6590–6598.
   PubMed Web of Science ®Google Scholar
• Nanki, T, and Lipsky, PE, 2000. Cutting edge: stromal cell‐derived factor‐1 is a costimulator for CD4+ T cell activation, J Immunol 164 (2000), pp. 5010–5014.
   PubMed Web of Science ®Google Scholar
• Nanni, P, Forni, G, and Lollini, PL, 1999. Cytokine gene therapy: hopes and pitfalls, Ann Oncol 10 (1999), pp. 261–266.
   PubMedGoogle Scholar
• Nizard, P, Gross, DA, Babon, A, Chenal, A, Beaumelle, B, Kosmatopoulos, K, and Gillet, D, 2003. Anchoring cytokines to tumor cells for the preparation of anticancer vaccines without gene transfection in mice, J Immunother 26 (2003), pp. 63–71.
   PubMedGoogle Scholar
• Nomura, T, Hasegawa, H, Kohno, M, Sasaki, M, and Fujita, S, 2001. Enhancement of anti‐tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI‐1‐ligand chemokine and stromal cell‐derived factor‐1 alpha chemokine genes, IntJ Cancer 91 (2001), pp. 597–606.
   PubMedGoogle Scholar
• Peled, A, Petit, I, Kollet, O, Magid, M, Ponomaryov, T, Byk, T, Nagler, A, Ben‐Hur, H, Many, A, Shultz, L, et al., 1999. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4, Science 283 (1999), pp. 845–848.
   PubMed Web of Science ®Google Scholar
• Rivoltini, L, Gambacorti‐Passerini, C, Squadrelli‐Saraceno, M, Grosso, MI, Cantu, G, Molinari, R, Orazi, A, and Parmiani, G, 1990. In vivo interleukin 2‐induced activation of lymphokine‐activated killer cells and tumor cytotoxic T‐cells in cervical lymph nodes of patients with head and neck tumors, Cancer Res 50 (1990), pp. 5551–5557.
   PubMed Web of Science ®Google Scholar
• Salvadori, S, Gansbacher, B, Pizzimenti, AM, and Zier, KS, 1994. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL‐2‐secreting tumors, J Immunol 153 (1994), pp. 5176–5182.
   PubMed Web of Science ®Google Scholar
• Shi, M, Hao, S, Su, L, Zhang, X, Yuan, J, Guo, X, Zheng, C, and Xiang, J, 2005. Vaccine of engineered tumor cells secreting stromal cell‐derived factor‐1 induces T‐cell dependent antitumor responses, Cancer Biother Radiopharm 20 (2005), pp. 401–409.
   PubMedGoogle Scholar
• Sonn, CH, Hee Ryung, Yoon, In Ock, Seong, Mi‐Ra, Chang, Yong Chan, Kim, Han‐Chul, Kang, Seok‐Cheol, Suh, and Young Sang, Kim, 2006. MethA Fibrosarcoma Cells Expressing Membrane‐Bound Forms of IL‐2 Enhance Antitumor Immunity, J Microbiol Biotech 16 (2006), pp. 1919–1927.
   Google Scholar
• Soo Hoo, W, Lundeen, KA, Kohrumel, JR, Pham, NL, Brostoff, SW, Bartholomew, RM, and Carlo, DJ, 1999. Tumor cell surface expression of granulocyte‐macrophage colony‐stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model, J Immunol 162 (1999), pp. 7343–7349.
   PubMedGoogle Scholar
• Tepper, RI, and Mule, JJ, 1994. Experimental and clinical studies of cytokine gene‐modified tumor cells, Hum Gene Ther 5 (1994), pp. 153–164.
   PubMed Web of Science ®Google Scholar
• Tepper, RI, Pattengale, PK, and Leder, P, 1989. Murine interleukin‐4 displays potent anti‐tumor activity in vivo, Cell 57 (1989), pp. 503–512.
   PubMed Web of Science ®Google Scholar
• Tjuvajev, J, Gansbacher, B, Desai, R, Beattie, B, Kaplitt, M, Matei, C, Koutcher, J, Gilboa, E, and Blasberg, R, 1995. RG‐2 glioma growth attenuation and severe brain edema caused by local production of interleukin‐2 and interferon‐gamma, Cancer Res 55 (1995), pp. 1902–1910.
   PubMed Web of Science ®Google Scholar
• Townsend, SE, and Allison, JP, 1993. Tumor rejection after direct costimulation of CD8+ T cells by B7‐transfected melanoma cells, Science 259 (1993), pp. 368–370.
   PubMed Web of Science ®Google Scholar
• Vianello, F, Papeta, N, Chen, T, Kraft, P, White, N, Hart, WK, Kircher, MF, Swart, E, Rhee, S, Palu, G, et al., 2006. Murine B16 melanomas expressing high levels of the chemokine stromal‐derived factor‐ 1/CXCL12 induce tumor‐specific T cell chemorepulsion and escape from immune control, J Immunol 176 (2006), pp. 2902–2914.
   PubMed Web of Science ®Google Scholar
• Yei, S, Bartholomew, RM, Pezzoli, P, Gutierrez, A, Gouveia, E, Bassett, D, Soo Hoo, W, and Carlo, DJ, 2002. Novel membrane‐bound GM‐CSF vaccines for the treatment of cancer: generation and evaluation of mbGM‐CSF mouse B16F10 melanoma cell vaccine, Gene Ther 9 (2002), pp. 1302–1311.
   PubMed Web of Science ®Google Scholar
• Zhang, T, Somasundaram, R, Berencsi, K, Caputo, L, Gimotty, P, Rani, P, Guerry, D, Swoboda, R, and Herlyn, D, 2006. Migration of cytotoxic T lymphocytes toward melanoma cells in three‐dimensional organotypic culture is dependent on CCL2 and CCR4, Eur J Immunol 36 (2006), pp. 457–467.
   PubMed Web of Science ®Google Scholar
• Zier, K, Gansbacher, B, and Salvadori, S, 1996. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy, Immunol Today 17 (1996), pp. 39–45.
   PubMedGoogle Scholar